Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RADX vs QTTB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

QTTB Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–1 Matrix Metrics)

QTTB Overall Winner 6-Pillar Tally: RADX 0 – 5 QTTB (1 Tie) Matrix Metrics: RADX 1 – 8 QTTB

As of Nov 20, 2026, Q32 Bio Inc. (QTTB) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RADX carries a Unified Composite Score of 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin), whereas QTTB carries 40.8/100 (SELL) at $8.34 (N/M Forward P/E, 34.2% operating margin).

  • Defensive Composite Rating Caution: Although QTTB compares more favorably head-to-head, both RADX (41.1/100 SELL) and QTTB (40.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: RADX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9); meanwhile QTTB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RADX vs QTTB
RADX NASDAQ
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap $10.6M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 0.52β · 109% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.5%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.86 · SMA50: $1.15
QTTB NASDAQ Head-to-Head Winner
Q32 Bio Inc. Common Stock
Pharmaceutical Preparations
$8.34
-1.65% 1D
Market Cap $253.8M
TTM Revenue $179M
Forward P/E N/M
Beta / 30D Vol 0.02β · 40% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 23.0 Fund 54.0 Flow 71.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.8%), weak momentum, RSI 41
RSI-14: 40.9 · SMA20: $8.81 · SMA50: $8.93

6-Pillar Scorecard Institutional Category Breakdown (RADX 0 – 5 QTTB)

Columns: Metric · RADX · QTTB
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M 2.4x
PEG Ratio N/M N/M
EV / Revenue 0.8x N/M
2. Growth & Scale QTTB
Revenue Growth (YoY) -36.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M $179M
Market Cap $10.6M $253.8M
3. Profitability & Quality QTTB
Gross Margin N/A 70.3%
Operating Margin -411.6% 34.2%
Net Profit Margin 0.0% 60.0%
Return on Equity (ROE) -174.7% 24.0%
4. Balance Sheet & Cash Flow QTTB
Cash Generation (TTM) -$50M EBITDA -$67M
Cash Flow Margin N/A -37.3%
Net Cash / Leverage $1.48 Book/Sh · -174.7% ROE $947M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning QTTB
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 187.6% (42nd %ile)
Put/Call OI Skew Thin ADR Chain 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat QTTB
OpEx & R&D Intensity N/A 36.1% of Rev ($65M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RADX (1) vs QTTB (8)
Institutional Metric RADX QTTB Criterion Row Edge
Market Capitalization
Scale
$10.6M $253.8M Larger Scale QTTB
Trailing P/E Ratio
Valuation
N/M 2.4x Lower Multiple QTTB
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-36.9% +0.0% Higher Growth QTTB
Operating Margin (TTM)
Profitability
-411.6% 34.2% Higher Margin QTTB
Net Profit Margin
Profitability
0.0% 60.0% Higher Margin QTTB
Return on Equity (ROE)
Capital Efficiency
-174.7% 24.0% Higher ROE QTTB
52-Week Range Position
Momentum
0% ($1–$16) 30% ($2–$24) Stronger Trend QTTB
Beta / 30D Volatility
Risk Regime
0.52β · 109% Vol 0.02β · 40% Vol Lower Realized Risk QTTB
Unified Institutional Score
Composite Signal
41.1 / 100 (SELL) 40.8 / 100 (SELL) Higher Composite RADX
Trailing 12M Revenue (USD)
Operating Scale
$13M $179M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 70.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$50M EBITDA ($1.48 Book/Sh · -174.7% ROE) -$67M ($947M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon QTTB +28.41 pp
RADX: -33.64% · QTTB: -5.23%
3M Horizon QTTB +25.14 pp
RADX: -74.16% · QTTB: -49.02%
6M Horizon QTTB +133.33 pp
RADX: -86.24% · QTTB: +47.09%
1Y Horizon QTTB +379.75 pp
RADX: -86.35% · QTTB: +293.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RADX vs QTTB. Trailing 12-month operating profitability (RADX -411.6% vs QTTB 34.2%) and valuation multiples (RADX N/M vs QTTB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RADX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross MarginN/A
Op. Margin-411.6%
ROE / Fwd P/E-174.7% · N/M
QTTB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$179M
Gross Margin70.3%
Op. Margin34.2%
ROE / Fwd P/E24.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RADX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RADX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
QTTB BREAKDOWN
93d in phase · OBV NEUTRAL
Current IV 187.6%
IV Percentile 42nd %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact QTTB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RADX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.6M market capitalization and -411.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
QTTB Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $253.8M market capitalization and 34.2% operating margin.
OpEx & R&D Reinvestment 36.1% of Rev ($65M)
90D Engineering Disclosures 0 Published

Investor FAQ RADX vs QTTB Key Questions & Quantitative Answers

As of Nov 20, 2026, Q32 Bio Inc. (QTTB) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RADX carries a Unified Composite Score of 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin), whereas QTTB carries 40.8/100 (SELL) at $8.34 (N/M Forward P/E, 34.2% operating margin). Defensive Composite Rating Caution: Although QTTB compares more favorably head-to-head, both RADX (41.1/100 SELL) and QTTB (40.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: RADX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9); meanwhile QTTB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

QTTB leads the Growth & Scale pillar: RADX posts -36.9% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (N/A gross margin, -411.6% operating margin), compared with QTTB at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $179M TTM revenue (70.3% gross margin, 34.2% operating margin). On trailing 12-month operating scale, RADX generates $13M in USD-normalized revenue versus $179M for QTTB. In operating R&D and SG&A reinvestment, RADX deploys N/A (0 90-day corporate R&D disclosures) versus 36.1% of Rev ($65M) (0 disclosures) for QTTB.

RADX and QTTB trade at balanced relative valuation multiples. RADX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas QTTB trades at N/M Forward P/E, 2.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (-37.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RADX (-174.7% ROE) versus QTTB (24.0% ROE) capital efficiency.

In options market volatility and institutional positioning, RADX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 109% Vol realized risk). By comparison, QTTB carries 187.6% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.02β · 40% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.